
Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer
Maintenance niraparib (Zejula) plus bevacizumab (Avastin) showed promising activity for patients with platinum-sensitive ovarian cancer previously treated with a PARP inhibitor, according to results from the phase 2 NIRVANA-R trial (NCT04734665) presented …